BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 19, 2025
Breaking News: Trump administration impacts
See today's BioWorld Science
Home
» Merck Sharp & Dohme describes new orexin OX2 receptor agonists for sleep disorders
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
Merck Sharp & Dohme describes new orexin OX2 receptor agonists for sleep disorders
Nov. 28, 2023
Merck Sharp & Dohme LLC has identified orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia and narcolepsy.
BioWorld Science
Neurology/psychiatric
Patents
